Drug intelligence / Profile preview

LY6249492

Development stage: Unknown
Lead developer: Eli Lilly
Administration: Injection

Overview

**LY6249492** is an investigational pharmaceutical drug developed by Eli Lilly, currently in clinical trials for the treatment of obesity and overweight individuals, including those with type 2 diabetes. It is being evaluated as part of a Phase 2 chronic weight management master protocol (CWMM) to assess its safety and efficacy for chronic weight management[7][9]. The specific mechanism of action, drug class, and molecular modality have not been disclosed in available public sources as of the current date.

Beyond the preview

Go deeper on LY6249492.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY6249492.

Explore the full profile